On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Trump aims to impose tariffs on pharmaceutical imports to boost US production, but industry fears shortages and increased ...

WHEN COULD TRUMP ANNOUNCE PHARMA TARIFFS? Trump's executive order last week listed pharmaceuticals alongside lumber, semiconductors and other sectors that could be subject to investigation under ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for gastrointestinal and genitourinary cancers such as prostate-specific membrane antigen ...

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience. To access our Live RNS you must confirm you are a private ...

Scancell to Present Clinical Data from the Ongoing Phase 2 SCOPE Trial of SCIB1 at 2025 AACR Annual Meeting Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the ...

Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to ...

Merck’s latest clinical data puts a shiny new needle on its cancer blockbuster Keytruda, showing that a quick two-minute injection is just as effective as the old-school IV drip when paired with chemo ...

Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...